Ohio State's Wexner Medical Center and Allostatix(tm) team up to create new cutting-edge healthcare startup
Imagine having the ability to predict and prevent the occurrence of deadly disease even before it starts. Today, it's possible.
The Ohio State University Wexner Medical Center and Allostatix (tm) have joined forces to create the ultimate personalized healthcare company. The new venture, P44U, which launched from Ohio State's Center for Personalized Health Care, is changing the face of healthcare delivery and has the potential to thwart many chronic illnesses before they begin.
P44U will offer groundbreaking approaches to personalized health care in a new field known as P4 Medicine - predictive, preventive, personalized, and participatory medicine. The P4 Medicine program was created to deliver health care focused on bringing the right intervention or treatment to the right person at the right time to save money and improve outcomes. The future of medicine will utilize advances in genomics and molecular diagnostics to provide predictive information that is necessary to tailor, or personalize, disease-management approaches for each individual. Therapeutics and health management tools are being developed to help prevent disease instead of merely treating the symptoms. Medicine of the future will also be participatory. These P4 treatment guidelines, intervention programs and behavioral modification methods are just some of the unique offerings licensed to P44U.
"Using extremely sophisticated analytics, we have the ability to test a healthy person and predict, with scientific accuracy, how an individual's wellness is today and what it will be in 3-5 years," said Gordon Horwitz, Founder and CEO of Cincinnati-based Allostatix(tm). "The testing results are personalized to the nth degree."
The vision for P44U stemmed from Dr. Clay Marsh, Executive Director of Ohio State's Center for Personalized Health Care and Vice Dean for Research in the College of Medicine.
"The goal of P44Uand P4 Medicine is to enable the delivery of key evidence-based practices to reduce healthcare costs and improve outcomes. This methodology leverages the interface between an individual's unique DNA, environment and behavior to promote health and wellness, ultimately delivering higher quality health care to our patients. P44U will utilize advances in genomics and molecular diagnostics discoveries to provide predictive information that is necessary to tailor, or personalize, disease management approaches for each individual," said Marsh.
Ohio State's Technology Commercialization and Knowledge Transfer Office (TCO) immediately saw the potential.
"The healthcare industry is desperate for new tools that more accurately track, monitor, and motivate patients toward a healthier lifestyle and the P44U platform represents such a tool that generates long-term benefits for healthcare reform and patient wellness," said Brian Cummings, Vice President of Technology Commercialization for Ohio State.
TCO made P44U possible by bringing the parties together through creation of the new start-up company, which will further develop new neural networks into a more robust health and wellness platform.
"As with any new intellectual property, the TCO did an assessment of the potential of the technology and the willingness of the parties to work together; it was a synergistic relationship between OSU's P4 Medicine program and Allostatix(tm) so the formation of a new company was an easy next step," said Cummings. "The P44U platform could become a standard for health and wellness screening across the country."
The new partnership predicts big impacts from the startup.
"The level of commitment and professional expertise from the TCO and OSUMC staff has exceeded my expectations. We are delighted to have such a well-respected, forward thinking institution like The Ohio State University as a partner in bringing our Allostatix Risk Prediction Systems (ARPS(tm)) to the world," said Gordon Horwitz. "This partnership has the ability to raise the bar in health and wellness programs and stop the march towards chronic illness by combining high-level analytics with P4 Medicine to create the gold standard of workplace wellness programs and personalized patient care."
About Allostatix, LLC
Cincinnati, Ohio-based Allostatix LLC is the creator of the Allostatix Risk Prediction System (ARPS Technology(tm)), which uses neural networks as the core of its analytic engine to aggregate health data and predict disease and premature death in healthy people, 3-5 years in advance. The company's predictive risk tools use blood and biometric results in its analysis and is based on 25 years of longitudinal medical research. Allostatix's Scientific Advisory Board consists of industry-leading research MDs and PhDs from UCLA, Rockefeller University, Stanford University, the University of Pittsburgh and the University of Cincinnati. For more information, see http://www.allostatix.com/.
About The Ohio State University Center for Personalized Health Care:
At the Center, we facilitate and advocate for the creation and practice of health care methods that combine an individual's genetic information with environmental, behavioral, and cultural factors, producing a tailored approach to the maintenance of good health and the prevention of disease. For more information, see http://www.cphc.osu.edu/.